

Table S1 234 lipid metabolism-related genes

ABCA1	CYP24A1	MED30	PNPLA2
ABCA3	CYP26A1	MED31	PPARA
ABCB1	CYP27B1	MED4	PPARD
ABCB11	CYP2B6	MED6	PPARG
ABCB4	CYP2C9	MED7	PPARGC1A
ABCC2	CYP2E1	MED8	PPARGC1B
ABCC3	CYP3A4	MED9	PRELID1
ABCD2	CYP4A11	MIR33A	PRELID2
ABCD3	CYP4B1	MIR33B	PRELID3A
ABCG1	CYP7A1	MTF1	PRELID3B
ABCG5	CYP8B1	MTTP	PRKAA1
ABHD5	EP300	NCOA1	PRKAA2
ACACA	ESRRA	NCOA2	PRKAB1
ACADM	ESYT1	NCOA3	PRKAB2
ACLY	FABP1	NCOA6	PRKACA
ACOX1	FADS1	NCOR1	PRKACB
ACSBG1	FAM120B	NCOR2	PRKACG
ACSL1	FASN	NFYA	PRKAG1
ACSS2	FDFT1	NFYB	PRKAG2
ADIPOQ	FHL2	NFYC	PRKAG3
AGT	G0S2	NPAS2	PRKAR1A
AHR	GLIPR1	NR1D1	PRKAR1B
AKT1	GLTP	NR1H2	PRKAR2A
AKT2	GLTPD2	NR1H3	PRKAR2B
AKT3	GPS2	NR1H4	PTGS2
ALAS1	GRHL1	NR1I2	RARA
ALOX5	HDAC3	NR1I3	RARB
ANGPTL4	HELZ2	NR3C1	RARG
ANKRD1	HILPDA	NRF1	RETN
APOA1	HMGCR	OSBPL2	RGL1
APOA2	HMGCS1	OSBPL5	RORA
APOA5	HMGCS2	OSBPL8	RXRA
ARNT	HRAS	PDHA1	RXRB
ARNT2	HSD11B1	PEX11A	SIN3A
ATG2A	LIPE	PITPNA	SIN3B
ATG2B	LPL	PITPNB	SLC27A1

Table S1 (continued)

Table S1 (continued)

<i>BCKDHA</i>	<i>ME1</i>	<i>PITPNC1</i>	<i>SLCO2A1</i>
<i>BLTP1</i>	<i>MED1</i>	<i>PITPNM1</i>	<i>SMARCD3</i>
<i>BLTP3B</i>	<i>MED10</i>	<i>PITPNM2</i>	<i>SP1</i>
<i>BMAL1</i>	<i>MED11</i>	<i>PITPNM3</i>	<i>SREBF1</i>
<i>C2CD2L</i>	<i>MED12</i>	<i>PLA2G10</i>	<i>SREBF2</i>
<i>CARM1</i>	<i>MED13</i>	<i>PLA2G12A</i>	<i>SULT2A1</i>
<i>CCNC</i>	<i>MED13L</i>	<i>PLA2G12B</i>	<i>TBL1X</i>
<i>CD36</i>	<i>MED14</i>	<i>PLA2G1B</i>	<i>TBL1XR1</i>
<i>CDK19</i>	<i>MED15</i>	<i>PLA2G2D</i>	<i>TGS1</i>
<i>CDK8</i>	<i>MED16</i>	<i>PLA2G3</i>	<i>THRAP3</i>
<i>CDKN1A</i>	<i>MED17</i>	<i>PLA2G4A</i>	<i>TIAM2</i>
<i>CERT1</i>	<i>MED18</i>	<i>PLA2G4C</i>	<i>TNF</i>
<i>CHD9</i>	<i>MED19</i>	<i>PLA2G4D</i>	<i>TNFAIP8L3</i>
<i>CIDEA</i>	<i>MED20</i>	<i>PLA2G4E</i>	<i>TNFRSF21</i>
<i>CIDEB</i>	<i>MED21</i>	<i>PLA2G4F</i>	<i>TP53</i>
<i>CIDEC</i>	<i>MED22</i>	<i>PLA2G5</i>	<i>TRIAP1</i>
<i>CLOCK</i>	<i>MED23</i>	<i>PLA2G6</i>	<i>TRIB3</i>
<i>CPT1A</i>	<i>MED24</i>	<i>PLA2G7</i>	<i>TTPA</i>
<i>CPT2</i>	<i>MED25</i>	<i>PLEKHA8</i>	<i>TXNRD1</i>
<i>CPTP</i>	<i>MED26</i>	<i>PLEKHA8P1</i>	<i>UGT1A9</i>
<i>CREBBP</i>	<i>MED27</i>	<i>PLIN1</i>	<i>VDR</i>
<i>CYP1A1</i>	<i>MED28</i>	<i>PLIN2</i>	
<i>CYP1A2</i>	<i>MED29</i>	<i>PLTP</i>	




Figure S1 The results of the LASSO Cox regression analysis. (A) The coefficient profiles of the candidate genes. (B) Six risk factors selected using LASSO Cox regression analysis.




Figure S2 The relationship between LMR gene signatures and immune checkpoints (*, $P \leq 0.05$; **, $P \leq 0.01$; ***, $P \leq 0.001$; ****, $P \leq 0.0001$).




Figure S3 The correlation between LMR gene signatures and immune cell infiltration.